Cargando…
A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors
INTRODUCTION: Immune-related adverse events (ir-AEs) are increasingly becoming a concern, as immune checkpoint inhibitors (ICIs) are used more frequently. Herein, we present a case of fulminant cytokine release syndrome (CRS) complicated by dermatomyositis after the combination therapy with ICIs. PA...
Autores principales: | Ohira, Junichiro, Kawamoto, Michi, Sugino, Yoshio, Kohara, Nobuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220092/ https://www.ncbi.nlm.nih.gov/pubmed/32282733 http://dx.doi.org/10.1097/MD.0000000000019741 |
Ejemplares similares
-
Begelomab for severe refractory dermatomyositis: A case report
por: De Lorenzo, Rebecca, et al.
Publicado: (2021) -
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
por: Corominas, Hèctor, et al.
Publicado: (2021) -
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
por: Yuan, Xin, et al.
Publicado: (2021) -
Pregnancy complicated with agranulocytosis
por: Wang, Hai, et al.
Publicado: (2016) -
Alterations of gut microbiota and cytokines in elevated serum diamine oxidase disorder
por: Shi, Lintao, et al.
Publicado: (2022)